Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 11.8% in September

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 245,300 shares, a growth of 11.8% from the August 31st total of 219,400 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average trading volume of 3,650,000 shares, the short-interest ratio is presently 0.1 days.

Hoth Therapeutics Price Performance

NASDAQ HOTH traded down $0.02 during trading on Tuesday, hitting $0.86. 84,340 shares of the company’s stock traded hands, compared to its average volume of 1,446,657. The firm has a market cap of $4.61 million, a P/E ratio of -0.44 and a beta of 0.82. The stock has a fifty day moving average of $0.82 and a two-hundred day moving average of $1.03. Hoth Therapeutics has a 12-month low of $0.58 and a 12-month high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.15. As a group, analysts expect that Hoth Therapeutics will post -1.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. EF Hutton Acquisition Co. I upgraded Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research report on Friday, August 16th.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.